Sidley represented Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, in the acquisition of Denali Medpharma, a leading China-based bioanalytical CRO. Resolian has bioanalysis laboratory operations in the U.S., UK, Australia, and China.
The multidisciplinary Sidley team was led by partner Ruchun Ji. The transaction involved a cross-border team working across several practice areas, including the following:
- Corporate and M&A: partner Ruchun Ji, senior managing associate Jing Peng and counsel Ling Chen;
- Regulatory: senior counsel Chen Yang and senior managing associate Mulai Xu;
- Tax: partner Oliver Currall; and
- Antitrust: partner Patrick Harrison, and associates Iva Todorova and Fiona Shajko.
Sidley’s Global Life Sciences practice, which comprises more than 200 dedicated lawyers globally, offers cross-disciplinary, full-service solutions for life science clients, ranging from M&A and private equity, licensing and collaboration transactions, capital markets, regulatory compliance and enforcement, and dispute resolutions, assisting biotech and pharmaceutical clients around the world. Sidley’s China Life Sciences practice, an integral part of the firm’s Global Life Sciences practice, is the only Band One international firm ranked by Chambers Asia Pacific/Greater China Region for 14 consecutive years.
